Department of Health Sciences, University of Florence, Viale Pieraccini, 6, 50139 Florence, Italy.
Department of Biology & Biochemistry, University of Bath, Bath BA2 7AY, United Kingdom.
Immunotherapy. 2019 Jun;11(9):759-768. doi: 10.2217/imt-2019-0011. Epub 2019 May 6.
Gastric cancer (GC) is the fifth most common malignancy and the third cause of cancer-related deaths worldwide. Currently, surgery and chemotherapy remain the main therapeutic options and the prognosis of the disease is still poor in the metastatic setting. Avelumab is a human IgG1 antibody directed against PD-L1 approved for Merkel cell carcinoma and urothelial carcinoma that could be useful also for the treatment of GC. This review describes the chemical structure, the pharmacologic properties and the current knowledge of the efficacy of avelumab in the treatment of GC from the data available on the first and later phase clinical trials. The ongoing studies testing this drug either alone or in combination with other drugs are also described.
胃癌（GC）是全球第五大常见恶性肿瘤，也是癌症相关死亡的第三大原因。目前，手术和化疗仍然是主要的治疗选择，转移性疾病的预后仍然很差。avelumab 是一种针对 PD-L1 的人源 IgG1 抗体，已被批准用于 Merkel 细胞癌和尿路上皮癌，也可能对胃癌的治疗有用。这篇综述描述了 avelumab 的化学结构、药理特性以及现有临床试验数据中该药在治疗 GC 方面的疗效。还描述了正在进行的单独或联合其他药物测试该药的研究。
